What is the Insulet Corporation stock price forecast?

Insulet Corporation is currently trading at $149.70. View real-time AI analysis on Alpha Lenz.

What is Insulet Corporation insider trading activity?

View the latest insider trading data for Insulet Corporation on Alpha Lenz.

What is Insulet Corporation's P/E ratio?

Insulet Corporation's P/E ratio is 42.6.

Insulet Corporation

NASDAQ · PODD

$149.70+0.51(+0.34%)Pre-market

Ask about Insulet Corporation's future dividend policy...

Alpha Chat Insight

“Insulet Corporation trades at a P/E of 42.6 (premium valuation) with strong ROE of 18.1%. 3Y revenue CAGR of 27.5% highlights clear growth momentum.”

Ask for details →

Company Overview

Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.

CEOMs. Ashley A. McEvoy

Websitehttps://www.insulet.com

SectorHealthcare

IndustryMedical Devices

Employees3,900

Company Statistics

FY 2025

Profile

$10.53BMarket Cap

$2.71BRevenue

0.00Shares Out

3,900Employees

Margins

71.63%Gross

22.18%EBITDA

17.50%Operating

12.54%Pre-Tax

9.12%Net

Valuation

42.62P/E

6.95P/B

3.89EV/Sales

17.92EV/EBITDA

30.10P/FCF

Growth (CAGR)

27.54%Rev 3Yr

24.53%Rev 5Yr

132.70%Op Inc 3Yr

55.87%Op Inc 5Yr

277.32%Net Inc 3Yr

105.15%Net Inc 5Yr

Returns

7.87%ROA

18.12%ROE

12.71%ROIC

Financial Health

$716.10MCash & Cash Equivalents

$959.00MNet Debt

110.55%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Insulet Corporation trades at a P/E of 42.6 (premium valuation) with strong ROE of 18.1%. 3Y revenue CAGR of 27.5% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Insulet Corporation (ticker: PODD) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 3,900 employees. Market cap is $10.5B.

The current price is $149.7 with a P/E ratio of 42.62x and P/B of 6.95x.

ROE is 18.12% and operating margin is 17.50%. Annual revenue is $2.7B.